Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. MicroPort Scientific Corporation
  6. News
  7. Summary
    853   KYG608371046


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

MicroPort Scientific : Endovastec™ Debuts at Pan-American Congress on Vascular and Endovascular Surgery

10/25/2021 | 03:34am EST

Rio de Janeiro, Brazil, 23 October 2021 - Shanghai MicroPort Endovascular MedTech Co., Ltd. (Endovastec™) recently debuted two flagship products at the XVI Pan American Congress on Vascular and Endovascular Surgery (PAN 2021). Endovastec™ debuted both the CastorTM Branched Aortic Stent-Graft System (Castor™ Stent) and the Minos™ Abdominal Aortic Stent-Graft and Delivery System (Minos™ Stent Graft System). As the most prestigious congress for endovascular surgery in Latin America, the virtual conference was attended by about 40 experts, prompting discussions relating to a variety of relevant topics, including aortic aneurysm, aortic arch, aortoiliac occlusive disease and COVID-19 complications.

Castor™ and Minos™ have won the recognition of experts and demonstrated excellent performance in clinical applications in many countries across Europe and South America. At the conference, Professor Chang Shu, Director of the Vascular Surgery Center at Fuwai Hospital of Chinese Academy of Medical Sciences shared the results of a clinical study on Castor™, as well as his insights on using TEVAR technology for aortic aneurysm with a challenging proximal neck - an important topic in the field of endovascular intervention.

Professor Chang Shu commented, "The Castor™ stent is the world's first stent-graft system for simultaneous aorta and aortic arch repair through minimally invasive treatment. Its unique unibody structure can not only adapt to a variety of arch anatomies, but also provides a creative solution to the access and positioning issues of unibody branched stent-grafts. As a result, it supports the convenient reconstruction of the left subclavian artery while avoiding potential gutter endoleaks caused by the chimney technique or long-term stability risks resulting from the window technique. It also reduces the risk of stent migration in the long term."

In addition, the Minos™ system was also presented to showcase its tri-modular design, which enables flexible assembly to accommodate different size requirements. The main body, constructed from laser-cutting bare stent hooks with integrated barbs, is covered with seamless woven graft, and its iliac limbs are woven by a single wire in a helical pattern. The advanced core technologies are able to meet the treatment needs of a wider range of abdominal aortic aneurysms with complex anatomy, which reduces the rate of complications, such as device migration, endoleaks, or occlusion, and thus lowers the risk of long-term reintervention.

About Shanghai MicroPort Endovascular MedTech Co., Ltd.

Shanghai MicroPort Endovascular MedTech Co., Ltd. is a subsidiary of MicroPort Scientific Corporation (00853.HK). As it continues to make its products available in new markets, Endovastec™ will also continue to strengthen in-depth collaboration with international clinical specialists, share clinical experiences and actively participate in academic conferences at home and abroad to promote academic exchange on aortic diseases, so that more medical solutions from China can benefit a greater number of patients and doctors worldwide.


MicroPort Scientific Corporation published this content on 23 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 October 2021 07:33:11 UTC.

© Publicnow 2021
11/26MicroPort MedBot's Underwriters Fully Exercise Hong Kong IPO's Overallotment Option at ..
11/24MICROPORT SCIENTIFIC : Mona Lisa Robotic Prostate Puncture System Completes Enrollment of ..
11/21MICROPORT SCIENTIFIC : ® Coronary Balloon Dilation Catheters Firefighter™ and Firefi..
11/18MICROPORT SCIENTIFIC : ® RehabTech TherMotion® Cryo-Thermo Compression Device Approved for..
11/17MICROPORT SCIENTIFIC : ® Announces Multiple Results from the TARGET Clinical Study on Fire..
11/17MICROPORT SCIENTIFIC : ® MedBot Launches DFVision® 3D Electronic Laparoscope at the 28th N..
11/15MICROPORT SCIENTIFIC : Ryflumen®, First Peripheral High-Pressure Balloon Dilatation Cathet..
11/14MicroPort MedBot Raises $29 Million from Full Exercise of Hong Kong IPO's Overallotment..
11/11MicroPort Scientific's Neurovascular Unit Raises $150 Million in CICC-Backed Funding Ro..
11/11MicroPort® Establishes Headquarters for the Americas in USA, with Southern California I..
More news
Financials (USD)
Sales 2021 780 M - -
Net income 2021 -169 M - -
Net cash 2021 672 M - -
P/E ratio 2021 -47,0x
Yield 2021 0,06%
Capitalization 7 833 M 7 832 M -
EV / Sales 2021 9,18x
EV / Sales 2022 7,77x
Nbr of Employees 8 303
Free-Float 47,2%
Duration : Period :
MicroPort Scientific Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 8
Last Close Price 4,37 $
Average target price 7,67 $
Spread / Average Target 75,7%
EPS Revisions
Managers and Directors
Zhao Hua Chang Chairman & Chief Executive Officer
Hong Bin Sun Chief Financial Officer
Qi Yi Luo Chief Technology Officer
Glendy Wang Chief Operating Officer
Jonathan H. Chou Independent Non-Executive Director
Sector and Competitors